Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.37 |
| ▸ | CTSB | P07858 | 4/20 | 0.37 |
| ▸ | CTSS | P25774 | 4/20 | 0.37 |
| ▸ | CTSK | P43235 | 4/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.34 |
| ▸ | FEN1 | P39748 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | DHODH | Q02127 | 3/20 | 0.32 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156327 | 0.87 | CTSL (0.43) | CTSLCTSBCTSSCTSKCYP3A4 | |
| SCHEMBL6364259 | 0.81 | CTSL (0.42) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2155546 | 0.75 | CTSL (0.42) | CTSLCTSBCTSSCTSKCYP3A4 | |
| SCHEMBL2155726 | 0.74 | SLC1A3 (0.44) | CTSLCTSBCTSSCTSKAAK1 | |
| SCHEMBL2156545 | 0.74 | CTSL (0.50) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2156630 | 0.74 | CTSL (0.50) | CTSLCTSBCTSSCTSK | |
| SCHEMBL6364135 | 0.74 | CTSL (0.65) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2155876 | 0.71 | CTSK (0.44) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2157314 | 0.71 | CTSL (0.39) | CTSLCTSBCTSSCTSK | |
| SCHEMBL2156402 | 0.70 | CTSL (0.48) | CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2005-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | CTSE, CTSS, CTSB | CTSL 7/4885CTSB 3/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.